The Dolphins wideout has dealt with a groin injury the last two weeks - and a new QB may not provide enough of a boost.
The Dolphins wideout has dealt with a groin injury the last two weeks - and a new QB may not provide enough of a boost.
Australia is bracing for a scorching weekend, with fire warnings stretching across several states.
Liverpool have the just to go top of the Premier League when they travel to Brighton for Saturday’s lunchtime kick-off. The Reds currently trail leaders Tottenham on goal difference, but with Spurs facing a tricky clash with Chelsea on Sunday, Jurgen Klopp’s men have the chance to put on some early title-race pressure. The German rotated his side for the Champions League group stage meeting with Atalanta but the move backfired as the Italians ran out 2-0 winners at Anfield.
French President Emmanuel Macron says images showing police beating up a black man '"shame us" and has called for ways to restore confidence in the force.
Marcus Wyatt claimed Britain's first men's skeleton World Cup medal for seven years by finishing third in Sigulda on Friday. The 28-year-old's bronze came following a strong second run which propelled him from sixth after his opening run to the final podium place behind Latvian home favourites Martins and Tomass Dukurs. It bettered Wyatt's previous World Cup best of fourth in Igls from January this year and also marked Britain's best men's result in the competition since Dom Parsons claimed bronze in Calgary in November 2013. Parsons, now retired, subsequently went on to win an Olympic medal of the same colour in PyeongChang just short of three years later. A former American football player, Wyatt was inspired to take up the sport after watching Lizzy Yarnold win the first of her two career Olympic gold medals at Sochi 2014. He took part in UK Sport's talent identification programme 'Power2Podium and made his World Cup debut in Dec 2017. “I can’t stop saying how crazy it is - it’s something I’ve always dreamt of,” he said. “I’m a bit speechless really. To be on the podium with the Dukurs brothers is pretty special. We’ve got a great group here and I can’t thank the team enough for helping me get to this point.
GUADALAJARA, Mexico, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (the “Company” or “GAP”) announced that it has concluded the Extraordinary Review Process for the Master Development Program for the Mexican airports for the 2020 to 2024 period. During the month of August, the Company filed a proposal for the adjustment of the Master Development Program (MDP) to the Aeronautical Authority, thus postponing investments by approximately 20 months. As such, certain investments that were scheduled to conclude in 2024 will now conclude in 2026.In the new MDP, the same projects that were previously agreed upon with the authorities will remain, however, the initiation and termination timeframes will change; the scope of the projects will essentially remain the same.The mandatory investment amounts of the Master Development Program that resulted from the Extraordinary Review were the following:Airport20202021202220232024TOTAL Guadalajara1,095,7121,148,5231,843,1551,063,2671,180,1326,330,791 Tijuana796,9431,465,857438,001161,784118,3822,980,967 Los Cabos395,869496,216272,952236,278177,9281,579,243 Puerto Vallarta205,956450,956660,397901,625807,6783,026,612 Guanajuato57,39088,61433,27369,52153,081301,879 Hermosillo57,95993,97053,06629,84956,805291,649 La Paz115,81992,34340,96824,12920,773294,032 Mexicali32,38547,81846,07757,67223,755207,708 Aguascalientes78,88398,10653,67626,33923,040280,044 Morelia32,71651,57635,09850,68219,510189,582 Los Mochis40,42640,98011,06953,33831,097176,911 Manzanillo26,43948,62930,17621,75715,670142,671 TOTAL2,936,5004,123,5883,517,9092,696,2402,527,85115,802,088 Figures are expressed in thousands of Mexican pesos with acquisition power as of December 31, 2017; as such these will be updated based on the National Producer Price Index (NPPI), construction sector, upon execution. As a result of the change in committed investments, as well as the remaining assumptions included in the Extraordinary Review, the new Maximum Tariffs that are applicable per workload unit are the following:Airport2021202220232024 Guadalajara216.86215.34213.83212.33 Tijuana165.57164.41163.26162.12 Los Cabos304.93302.80300.68298.58 Puerto Vallarta303.71301.58299.47297.37 Guanajuato226.89225.30223.72222.15 Hermosillo169.49168.30167.12165.95 La Paz186.65185.34184.04182.75 Mexicali162.06160.93159.80158.68 Aguascalientes175.50174.27173.05171.84 Morelia265.85263.99262.14260.31 Los Mochis192.76191.41190.07188.74 Manzanillo232.02230.40228.79227.19 These passenger charges have been adjusted at an annual efficiency rate of 0.7% and are expressed in Mexican pesos as of December 31, 2017, as such, they will be updated per the National Producer Price Index (NPPI), excluding petroleum. Company Description: Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concesiones Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the operation of the Norman Manley International Airport in Kingston, Jamaica. In October 2018, GAP entered into a concession agreement for the operation of the Norman Manley International Airport in Kingston, Jamaica and took control of the operation in October 2019. This press release may contain forward-looking statements. These statements are statements that are not historical facts, and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations and the factors or trends affecting financial condition, liquidity or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends or results will actually occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations. In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that June involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party that is in charge of collecting these complaints, is 01 800 563 00 47. The web site is www.lineadedenuncia.com/gap. GAP’s Audit Committee will be notified of all complaints for immediate investigation. IR Contacts: Saúl Villarreal, Chief Financial Officersvillarreal@aeropuertosgap.com.mx Alejandra Soto, IR, Finance and Financial Planning Managerasoto@aeropuertosgap.com.mx Gisela Murillo, Investor Relationsgmurillo@aeropuertosgap.com.mx / +52-33-3880-1100 ext.20294 Maria Barona, i-advize Corporate Communicationsmbarona@i-advize.com
Roy Hodgson says Crystal Palace must create more chances if they are to pick up results after back-to-back defeats. Two late Newcastle goals at Selhurst Park on Friday night saw Palace defeated 2-0, with the Eagles guilty of a slow start against Steve Bruce's side. Hodgson, who was without star man Wilfried Zaha following a positive coronavirus test, said it was not a display to be proud of and that the south Londoners must get back on track before facing West Brom next week.
It was joy for Lachlan Coote and despair for Bevan French as St Helens defeated Wigan 8-4 in Friday's Super League grand final.
VANCOUVER, British Columbia, Nov. 27, 2020 (GLOBE NEWSWIRE) -- GT Gold Corp. (TSX-V:GTT ; OTCQX:GTGDF) (the “Company” or “GT Gold”) reports its unaudited financial results for the quarter ended September 30, 2020. Copies of both the Financial Statements and the Management’s Discussion & Analysis may be obtained on the Company’s website at www.gtgoldcorp.ca or under the Company profile on SEDAR. “I am very pleased with the progress made by the team in 2020,” commented Paul Harbidge, President and Chief Executive Officer. “We have safely navigated through the challenges associated with COVID-19 and have successfully completed the exploration field season at Quash Pass. In addition, we have now begun the Saddle South core re-logging program. At Saddle North, we have achieved the milestone of maiden resource and it is proving an exciting time for GT Gold as we continue, well-financed and on track to deliver a Preliminary Economic Assessment in early 2021.” Highlights of the third quarter and for the subsequent period up to November 27, 2020: * Financing announced. On November 2, the Company announced a fully subscribed non-brokered private placement financing (the “Financing”) for total gross proceeds of $5.7 million, to be used to fund general working capital and to advance 2021 exploration activities on the Company’s Tatogga property. On November 9, the Company announced it had closed the first tranche of the Financing for $1.39 million. * Operational update. On October 29, the Company provided an operational update with the following highlights: * The Company concluded exploration drilling for the season on October 25, after completing nine holes for 4,841 metres at Quash Pass. The Company is awaiting assay results. * The Company received the final metallurgical results for the nine samples to be used in preparation of the Preliminary Economic Assessment (“PEA”), with metal recovery results between 85% to 92% for copper and 57% to 69% for gold, an improvement over the previously released metallurgical results. * The Company continues to advance the PEA, which envisions a combination of a starter pit that accesses the mineral resources to a vertical depth below surface of approximately 150 metres, and an underground bulk mining operation, accessing the higher-grade copper-gold mineralized core through a decline. * The Company is initiating a comprehensive re-log of all Saddle South drill core. The program is designed to progress the Saddle South precious metal rich vein system through geological modelling in early 2021, with a maiden mineral resource estimate and economic evaluation expected to follow by year-end. * GT Gold commenced trading on the OTCQX. On October 20, the Company announced that its common shares will commence trading in the United States of America (“U.S.A.”) on the OTCQX. GT Gold has upgraded to OTCQX from the Pink® market. * New Director appointed. On September 16, Ms. Lana Shipley was appointed as a Non-Executive Director. Ms. Shipley is a corporate lawyer specializing in Indigenous and environmental law. * 43-101 Technical Report filed. On August 20, the Company filed a National Instrument 43-101 technical report to support the maiden Mineral Resource estimate for the Saddle North project, previously announced on July 6. The report highlighted the continuous higher-grade central core within the deposit, the simple metallurgy, the excellent local infrastructure and topography and the exploration upside of the property. The Mineral Resource estimate comprises an Indicated Resource of 298 Mt grading 0.28% copper, 0.36 g/t gold and 0.8 g/t silver for a total of 1.81 Blb of copper, 3.47 Moz of gold and 7.58 Moz of silver and an Inferred Resource of 543 Mt grading 0.25% copper, 0.31 g/t gold and 0.7 g/t silver for a total of 2.98 Blb of copper, 5.46 Moz of gold and 11.64 Moz of silver. The Mineral Resource will form the basis for a PEA, the release of which is targeted for the first quarter of 2021.At September 30, 2020, the Company had a cash position of C$9.4 million, which is expected to be sufficient to fund all expenditures up to and including the PEA, as well as to provide a sizeable buffer for work following into 2021, to be planned based on the results of the 2020 technical program.Qualified PersonIn accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects, Michael Skead, FAusIMM, Vice President Projects, is the Qualified Person for the Company and has validated and approved the technical and scientific content of this news release.About GT GoldGT Gold Corp. is focused on exploring for base and precious metals in the geologically fertile terrain of British Columbia’s renowned Golden Triangle. The Company’s flagship asset is the wholly-owned, 47,500 hectare Tatogga property, located near Iskut, BC, upon which it made two significant discoveries in 2017 and 2018 at its Saddle prospect: a precious metal rich vein system at Saddle South and a gold rich copper porphyry system at Saddle North. The Company has published a Mineral Resource estimate for Saddle North and is currently working to complete a Preliminary Economic Assessment, targeting release in the first quarter of 2021.For further information, please contact:GT Gold Corp. Paul Harbidge President and Chief Executive Officer Tel: (236) 427 5744 Website: www.gtgoldcorp.ca GT Gold Corp. Shawn Campbell Chief Financial Officer Tel: (236) 427 5744 firstname.lastname@example.org Cautionary Statement Regarding Forward Looking Statements This news release contains forward-looking statements and forward-looking information (together, "forward-looking statements") within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Generally, forward-looking statements can be identified by the use of terminology such as "plans", "expects”, "estimates", "intends", "anticipates", "believes" or variations of such words, or statements that certain actions, events or results "may", "could", "would", "might", "will be taken", "occur" or "be achieved". Forward looking statements involve risks, uncertainties and other factors disclosed under the heading “Risk Factors” and elsewhere in the Company’s filings with Canadian securities regulators, that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing these forward-looking statements are reasonable based upon the information currently available to management as of the date hereof, actual results and developments may differ materially from those contemplated by these statements. Readers are therefore cautioned not to place undue reliance on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
It seems the British star's ageless looks really do run in the family, as she poses up a storm with sister Kate Curran.
A 15th man has been arrested during an ongoing police operation targeting a global network sharing the sexual abuse of Australian children.
TORONTO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Waypoint Investment Partners Inc. (Waypoint) today announced the refiling of the Interim Management Report of Fund Performance (MRFP) for Waypoint All Weather Alternative Fund (the Fund). The purpose of the refiling is to: * correctly label the MRFP as Interim Management Report of Fund Performance which was improperly labelled as Annual Management Report of Fund Performance; * include the trading expense ratio for the Fund which is 1.13% and was incorrectly stated; * include information on the net asset value per unit at the end of the period which was omitted in the first chart under “Financial Highlights”; and * include information on the management expense ratio before waivers or absorptions which was omitted.The effect on the Fund of these corrections was immaterial and no other changes were made to the MRFP. The refiled MRFP will be available on the Fund’s website at http://www.waypointinvestmentpartners.com/funds.html and on SEDAR at www.sedar.com.Commissions, trailing commissions, management fees, and expenses all may be associated with investments in the Fund. Please read the prospectus and Fund Facts before purchasing the Fund. The Fund is not guaranteed. The net asset value of the Fund changes frequently and past performance may not be repeated.For further information on Waypoint and the Fund, please visit www.waypointinvestmentpartners.ca.ABOUT WAYPOINT INVESTMENT PARTNERSWaypoint Investment Partners Inc. is a Toronto-based investment manager that services high net worth individuals, family offices, investment advisors, foundations and institutional clients. With a team of 10 experienced industry professionals, Waypoint delivers unique and proprietary products and services. Waypoint is a member of the Portfolio Management Association of Canada and is registered as an Investment Fund Manager, Portfolio Manager and Exempt Market Dealer in several Canadian provinces.For further information, please contact Max Torokvei, Partner & Chief Executive Officer, email@example.com, (416) 960-7683.
Ethiopian forces have seized more Tigrayan towns and will control the capital in a few days, a senior officer says, as they continue their "final phase".
Mike Tyson says he never imagined as a heavyweight boxing champion that he would climb into the ring with Roy Jones Jr. at age 54 as he does on Saturday.
A ‘disgusted’ woman claims she discovered maggots in her McDonald’s order during a meal with her family.
ISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings Raise Concerns About Professional Past of WaterMill Nominee Holger WeisZiopharm Recommends Shareholders Return the GREEN Consent Revocation CardBOSTON, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a response to a report issued by Institutional Shareholder Services (“ISS”) in connection with the consent solicitation initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”). In its report, ISS recommends that Ziopharm shareholders reject WaterMill’s attempt to remove half of the Ziopharm Board of Directors (the “Board”) and to vote against the addition of Mr. Postma to the Board. Ziopharm strongly recommends shareholders sign and return the Company’s GREEN Consent Revocation Card.In a statement, the Company said:“We are gratified that ISS acknowledges that removing half of Ziopharm’s Board and replacing them with WaterMill’s full slate of proposed candidates – including Mr. Postma, himself – would not be in the best interest of shareholders or the Company. In addition, we are pleased that ISS acknowledges the track record of Ziopharm’s performance in recent years, which we believe underscores the long-term value potential in Ziopharm under the leadership of the current Board and management team. Importantly, while we have a great deal of respect for ISS, the report contains a number of factual mistakes. Additionally, key information in the public domain relating to WaterMill nominee Holger Weis raises questions regarding his suitability as a director.”The ISS report made clear several points relating to Ziopharm’s financial standing and performance, including by noting that “the company outperformed the median of its peer group since Tarriff assumed leadership of the board and since the company ended the Intrexon collaboration.”However, Ziopharm’s management team and Board believe it is critical for shareholders to be aware of the following factual errors in the ISS report: * ISS recommends in favor of fixing the Board size at seven, but their other recommendations would result in an eight-member board. * ISS states that the Board “rejected” the resignations of Elan Ezickson and Dr. Scott Braunstein, but that is not correct. In fact, the Board never rejected these resignations. The Board promptly engaged two leading search firms to identify candidates in connection with the results of the 2020 annual meeting and has accepted resignations as soon as it has found suitable replacements. * ISS reports Elan Ezickson attended “fewer than 75 percent of meetings in 2019”, which is not accurate. Mr. Ezickson attended nearly 90% of Board and committee meetings in 2019. Mr. Ezickson attended fewer than 75% of meetings the year before that only because he was unable to participate in two special Board meetings that were called on short notice. * ISS’ review of Ziopharm’s material weakness is incorrect. The ISS report notes “there is nothing that prohibits the company from disclosing that remediation is underway,” when in fact Ziopharm has disclosed the remediation steps in several filings with the U.S. Securities and Exchange Commission (the “SEC”), including in its most recent Form 10-Q filed on November 5, 2020. * ISS also critiques the Board for the “retention of an overboarded director,” but fails to note that the issue was remedied by the director’s resignation from another board well in advance of the launch of the consent solicitation. Additionally, ISS recommends in favor of the election of WaterMill nominee Holger Weis arguing, among other things, that he “served on a public company board”. However, the Company has not found any evidence that Mr. Weis has public company board experience, an assessment supported in WaterMill’s own disclosures. Moreover, shareholders should consider the following publicly available information relating to WaterMill nominee Holger Weis:1 * In July 2017, a majority of shareholders executed written consents to remove Mr. Weis as President, COO, and CFO of DemeRx, Inc. (“DemeRx”). Four days later, Mr. Weis resigned from the company. * Less than a year after Mr. Weis’s departure, DemeRx filed for Chapter 11 bankruptcy. Importantly, in response to Mr. Weis's creditor claim as part of the Chapter 11 bankruptcy filing, DemeRx claimed that Mr. Weis engaged in a breach of his fiduciary duties, corporate waste, misrepresentations of critical information to prospective shareholders about a clinical trial and misreporting of an FDA submission. Among other things, the DemeRx response notes the following:“Weis made inaccurate and misleading presentations to the Board indicating that he had achieved certain performance benchmarks, when in fact he had not, resulting in the payment of cash bonuses and other excessive remuneration.”“Weis engaged in corporate waste by awarding himself stock, a golden parachute, cash payments, and other excessive compensation based on milestones never achieved. Weis wrote his own performance evaluation. Weis painted a ‘rosy picture,’ overstated accomplishments and achievements and progress of a financing plan. Weis made unauthorized payments to himself on his last day of work, withdrawing all remaining funds from the [DemeRX’s] bank account. Weis also made certain to pay his future life insurance on his way out the door.”“The FDA put [DemeRX’s] research project on a ‘full clinical hold’ in 2014. A potential investor, Kieretsu Capital LLC (‘Kieretsu’) was interested in providing funding. Weis advised Keiretsu that ‘Noribogaine is now ready to enter phase 2 clinical testing.’ But DemeRx was not ‘ready’ because of the FDA’s full clinical hold imposed in 2014. Weis also advised Keiretsu that DemeRx had ‘addressed the FDA’s concerns,’ which was materially inaccurate, as DemeRx had not contacted the FDA since the time the hold was imposed in 2014.”“During that time Weis was in charge of [DemeRx], it is estimated that Weis caused corporate waste, damages, and harm to [DemeRx] in the amount of approximately $10-12 million as the direct result of their acts and omissions, including complete and utter failure to implement adequate safeguards and controls and complete lack of oversight, that caused [DemeRx] to engage in activities and other improvident conduct beyond the scope of the PPM and that was otherwise fundamentally flawed…”“Weis also ran up costs to DemeRx of over $868,000 in 2016 and incurring over $556,000 in debt to patent attorneys in 2016 when DemeRx had already received the ‘going concern’ opinion from the outside independent auditors. Weis engaged in corporate waste in regard to excessive patent prosecution and foreign annuity costs, putting critical IP at risk of abandonment due to lack of funds.”1 Objection to Claim filed by DemeRx, Inc., Case 18-14149-RAM (Document 125), filed November 5, 2018.Information related to the WaterMill consent solicitation can be found at www.ZiopharmForward.com.About Ziopharm Oncology, Inc. Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the business strategy, plans and objectives of Ziopharm management and expectations as to and beliefs about the Consent Solicitation initiated by WaterMill. Forward-looking statements include all statements that are not historical facts, and can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or similar expressions and the negatives of those terms. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Such risks and uncertainties include, among others, the impact and results of the Consent Solicitation and other shareholder activism activities by WaterMill and/or other activist investors, the risks and uncertainties disclosed in Ziopharm’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as well as discussions of potential risks, uncertainties and other important factors in any subsequent filings by Ziopharm with the SEC. All information in this press release is as of the date hereof, and Ziopharm undertakes no duty to update the information, except as required by law.Important Additional Information and Where to Find It Ziopharm has filed a definitive consent revocation statement (the “Consent Revocation Statement”) together with a GREEN consent revocation card with the SEC in connection with the Consent Solicitation. SHAREHOLDERS ARE URGED TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT ZIOPHARM FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders will be able to obtain, free of charge, copies of the Consent Revocation Statement (including the GREEN consent revocation card), any amendments or supplements thereto and any other documents that Ziopharm files with the SEC from the SEC’s website (http://www.sec.gov) or from Ziopharm’s website (www.ziopharm.com) by clicking on “Investors” and then “SEC Filings.”Investor Relations Contacts: Adam D. Levy, PhD, MBA EVP, Investor Relations and Corporate Communications (508) 552-9255 firstname.lastname@example.orgChris Taylor VP, Investor Relations and Corporate Communications (617) 502-1881 email@example.comMichael Verrechia Morrow Sodali (212) 300-2476 firstname.lastname@example.orgMedia Relations Contacts: Chris Kittredge, Andrew Cole and Zachary Tramonti Sard Verbinnen & Co. Ziopharm-SVC@sardverb.com
Frank Lampard says he is proud to have been associated with Chelsea during the Roman Abramovich era but will not rest until they are back at the pinnacle of the English game.
Get your hot cocoa ready (but keep it away from Frosty!).❄️
The person in charge of the Washington Twitter account might have had a little too much fun with the team's Thanksgiving win over the Cowboys.
Five people including day care educators have been arrested on charges of defrauding the Commonwealth by mis-claiming COVID-19 stimulus payments.
The S&P 500 and Nasdaq have closed a shortened week at a record high as investors favoured tech-related, market-leading stocks.